In conclusion, CAND1 is a negative regulator of NAFLD, which exerts its action by restraining the assembly of Cullin1, FBXO42 and ACAA2 complexes and inhibiting ubiquitinated degradation of ACAA2 (Fig. 9). The gene discussed is FBXO42; the disease is metabolic dysfunction-associated steatotic liver disease.